Kevin Gamett, MD
Ophthalmology · Reno, NVNPI 1073823258
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by NEW World Medical,inc. at 25.8% of the total.
Across 174 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$1K
- AbbVie$1K
- Alcon$944
- Aerie Pharmaceuticals, Inc.$380
- Sight Sciences, Inc.$304
- Biotissue Holdings Inc.$211
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 14 | $1,458 |
| AbbVie(2 entities) | 56 | $1,021 |
| Alcon | 24 | $944 |
| Aerie Pharmaceuticals, Inc. | 11 | $380 |
| Sight Sciences, Inc. | 9 | $304 |
| Biotissue Holdings Inc. | 10 | $211 |
| Tarsus Pharmaceuticals, Inc. | 6 | $182 |
| Oyster Point Pharma, Inc. | 4 | $182 |
| Glaukos Corporation | 5 | $144 |
| Novartis | 6 | $110 |
| Hoffmann-la Roche Limited | 1 | $99 |
| Apellis Pharmaceuticals, Inc. | 3 | $92 |
| Amgen(2 entities) | 4 | $90 |
| Rayner Intraocular Lenses Limited | 3 | $59 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $56 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $53 |
| Astellas Pharma US Inc | 2 | $52 |
| Kala Pharmaceuticals, Inc. | 2 | $35 |
| Harrow Eye, LLC | 1 | $32 |
| Optos, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Dompe US, Inc. | 1 | $22 |
| Rxsight Inc | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$1,336
- Clearpath$1,336
- Ahmed Glaucoma Valve$1,336
- Streamline$1,336
- Via360$658
- Hydrus Microstent$150
- Centurion$149
- OMNI(R) SURGICAL SYSTEM (US)$140
- SION SURGICAL INSTRUMENT$140
- TYRVAYA$121
- XEN GLAUCOMA TREATMENT SYSTEM$118
- XDEMVY$108
- Rhopressa$107
- Clareon$106
How this compares
$5,663 in reported general payments places this provider in the 75th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 185 | $101,332 |
| XiidraLifitegrast | 54 | $68,067 |
| RhopressaNetarsudil Mesylate | 118 | $56,874 |
| Prednisolone Acetate | 965 | $43,805 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $40,216 |
| Latanoprost | 1,987 | $32,377 |
| RestasisCyclosporine | 38 | $27,957 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 109 | $27,925 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 71 | $21,226 |
| Cyclosporine | 25 | $19,349 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 908 | $18,670 |
| Brimonidine Tartrate | 600 | $18,321 |
| Brinzolamide | 90 | $18,021 |
| Travoprost | 86 | $17,543 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $13,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Restasis Multidose, Alphagan P | $1,021 | $161,785293 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $380 | $97,090185 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $21 | $78,22471 claims |
| AlconSimbrinza | $944 | $21,22671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Reno
- Arshad KhananiReno$2M
- Steve ChangReno$75K
- Matthew MillsReno$15K
- Elena GeraymovychReno$14K
- Jamison EngleReno$6K
- Caleb MorrisReno$4K
- William DurantReno$4K
- Hardeep DhindsaReno$3K
- Peter FreemanReno$3K
- Xintong LiReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.